Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human adenovirus type 5 injection plus HAIC, sintilimab, and regorafenib in advanced hepatocellular carcinoma after first-line failure
ChiCTR2400085738Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Oncorine, sintilimab and regorafenib in hepatocellular carcinoma (HCC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: objective response rate. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
Oncorinesintilimabregorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400085738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085738.